Xoma Corp. preclinical data

XOMA presented preclinical data on possible lead candidates for treating fungal infections. As reported at the Interscience Conference on Antimicrobial Agents and Chemotherapy, in vivo activity was demonstrated in a mouse model for the peptides derived from amino acids 148-161 of BPI, or domain III of the molecule. Mice were challenged with intravenous Candida albicans, and peptides were given intravenously four times a day. Of the 53 peptides screened, 21 significantly prolonged survival compared to placebo (p<0.05). By comparison, amphotericin B completely protected all animals.

A target IND filing has been set for early 1997, although the company said that the candidate peptide has not been selected yet. ...